Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Debt to Equity (2016 - 2023)

Historic Debt to Equity for Amicus Therapeutics (FOLD) over the last 15 years, with Q2 2023 value amounting to $0.12.

  • Amicus Therapeutics' Debt to Equity rose 491.56% to $0.12 in Q2 2023 from the same period last year, while for Jun 2023 it was $0.12, marking a year-over-year increase of 491.56%. This contributed to the annual value of $0.17 for FY2022, which is 18306.48% up from last year.
  • As of Q2 2023, Amicus Therapeutics' Debt to Equity stood at $0.12, which was up 491.56% from $0.12 recorded in Q1 2023.
  • In the past 5 years, Amicus Therapeutics' Debt to Equity registered a high of $0.41 during Q2 2020, and its lowest value of $0.03 during Q4 2020.
  • Over the past 5 years, Amicus Therapeutics' median Debt to Equity value was $0.12 (recorded in 2023), while the average stood at $0.18.
  • In the last 5 years, Amicus Therapeutics' Debt to Equity skyrocketed by 150052.73% in 2019 and then tumbled by 8995.34% in 2020.
  • Amicus Therapeutics' Debt to Equity (Quarter) stood at $0.31 in 2019, then plummeted by 89.95% to $0.03 in 2020, then surged by 97.86% to $0.06 in 2021, then skyrocketed by 183.06% to $0.17 in 2022, then plummeted by 33.04% to $0.12 in 2023.
  • Its Debt to Equity was $0.12 in Q2 2023, compared to $0.12 in Q1 2023 and $0.17 in Q4 2022.